What are the reimbursement models for digital therapeutics?

This blog post has been written by the person who has mapped the digital therapeutics market in a clean and beautiful presentation

Digital therapeutics represent one of healthcare's most promising investment frontiers, combining software innovation with clinical validation to treat actual medical conditions.

The global DTx market reached $5.6 billion in 2024 and is projected to hit $45.6 billion by 2033, driven by expanding reimbursement pathways across major healthcare systems. Understanding these reimbursement models is crucial for entrepreneurs and investors looking to enter this rapidly evolving space.

And if you need to understand this market in 30 minutes with the latest information, you can download our quick market pitch.

What exactly qualifies as a digital therapeutic, and how is it different from wellness apps or telehealth platforms?

Digital therapeutics are software-based medical interventions that treat, manage, or prevent diagnosed medical conditions through evidence-based clinical protocols.

The FDA draws a clear regulatory line: DTx must demonstrate therapeutic claims for specific diseases through randomized controlled trials, while wellness apps promote general health without medical claims. Unlike telehealth platforms that simply deliver care remotely, DTx software IS the treatment itself.

DTx products require medical device approval (FDA 510k, CE mark, PMDA clearance) and are often prescribed by physicians. They integrate with electronic health records and clinical workflows. Akili's EndeavorRx for ADHD, for example, underwent rigorous clinical trials proving efficacy before FDA clearance, while meditation apps like Headspace remain unregulated wellness tools.

The regulatory distinction matters enormously for reimbursement. Payers only cover products with proven medical benefit and regulatory approval, making the evidence bar the key differentiator for market entry.

Which reimbursement pathways currently exist for digital therapeutics in the US, Europe, and Asia?

Reimbursement pathways have rapidly expanded across major healthcare systems, creating multiple routes to market for validated DTx products.

If you want to build on this market, you can download our latest market pitch deck here

What are the main business models used by companies offering digital therapeutics today?

DTx companies employ diverse business models depending on their target market, regulatory status, and payer relationships.

Prescription-based models leverage new HCPCS supply codes where physicians bill for DTx provision and ongoing monitoring through RTM/RPM codes. This approach works for chronic diseases like diabetes and ADHD where ongoing clinical oversight adds value. Companies like Akili use this model for EndeavorRx.

DiGA tariff models in Germany provide flat reimbursement averaging €423 per 90-day activation from statutory insurers. Kaia Health has built a profitable €21M ARR business primarily on German lives using this approach for musculoskeletal conditions.

Employer B2B subscriptions charge $15-50 per member per month with outcomes guarantees. Omada Health scaled to $189M revenue using this model for diabetes and obesity management, targeting self-insured employers who benefit directly from reduced healthcare costs.

Pharma co-marketing arrangements provide milestone payments plus 10%+ royalties on companion drug sales, allowing DTx companies to avoid patient acquisition costs while pharma partners gain differentiated digital offerings.

Need a clear, elegant overview of a market? Browse our structured slide decks for a quick, visual deep dive.

How do digital therapeutics companies typically generate revenue — direct-to-consumer, B2B, or through insurers?

Revenue generation has shifted dramatically toward B2B and payer reimbursement models as DTx companies scale beyond direct-pay consumers.

Insurer reimbursement now drives the highest volume and most sustainable revenue streams. UnitedHealth expanded DTx coverage to 43% of commercial members by 2024, up from 18% in 2022. Medicare's new HCPCS codes create the first national public payer pathway, with commercial insurers typically following Medicare precedent within 12-18 months.

Employer contracts generate substantial recurring revenue through per-member-per-month subscriptions. Large employers particularly value DTx for diabetes, obesity, and mental health where they can measure direct ROI through reduced pharmacy spend and absenteeism. This B2B channel offers lower customer acquisition costs and higher renewal rates than consumer models.

Direct-to-consumer remains viable mainly for mild conditions or DTx not yet covered by payers. However, DTC-only plays struggle with scalability due to high acquisition costs and price sensitivity. Most successful companies now use DTC as an entry point while building toward payer coverage.

Pharma partnerships provide an increasingly attractive alternative, combining milestone payments with ongoing royalties tied to drug prescriptions. CureApp's partnership with Shionogi for smoking cessation exemplifies this model's potential for sustainable growth.

Which payers are currently reimbursing digital therapeutics, and under what conditions?

Payer adoption has accelerated significantly with clear coverage criteria emerging across different payer types.

What are some real-world use cases where reimbursement has been successful?

Several DTx companies have achieved significant reimbursement success across different therapeutic areas and business models.

Akili Interactive's EndeavorRx became the first FDA-cleared video game medicine for ADHD in children, gaining coverage from Highmark and Cigna under prior authorization. The company also secured DiGA listing in Germany, providing dual-market reimbursement for the same product. Clinical trials showed measurable attention improvements, supporting payer confidence in outcomes.

CureApp achieved remarkable success in Japan with two reimbursed products: CureApp SC for smoking cessation and CureApp HT for hypertension, both covered under national insurance fee-schedule item A001. The company's partnership with Shionogi provides additional royalty revenue tied to companion drug sales, demonstrating the pharma co-marketing model's effectiveness.

Big Health scaled Sleepio for insomnia through NHS coverage after NICE approval, saving £15 per patient in primary care drug costs. The company simultaneously built employer contracts covering 800,000 lives through Evernorth's digital formulary, proving multi-channel reimbursement strategies work.

Kaia Health achieved profitability on German DiGA reimbursement alone, generating €21M ARR from musculoskeletal and COPD programs. The company now files for PECAN fast-track approval in France, expanding its European footprint.

Omada Health demonstrates the employer model's scale potential, reaching $189M revenue pre-IPO through contracts with self-insured employers for diabetes and obesity management, achieving 25-30% operating margins at scale.

If you want actionable data about this market, you can download our latest market pitch deck here

What are the most profitable reimbursement models so far in 2025, and what market segments are driving them?

Subscription models combined with outcomes-based guarantees command the highest gross margins, often exceeding 70% once companies achieve scale.

Employer B2B contracts prove most profitable due to low customer acquisition costs and high renewal rates. Omada Health's PMPM model reaches 25-30% operating margins with predictable recurring revenue. Large employers value measurable ROI through reduced pharmacy costs and absenteeism, particularly for diabetes, obesity, and mental health conditions.

Germany's DiGA tariff model offers exceptional profitability with flat reimbursement averaging €423 per 90-day activation. Kaia Health built a profitable business on German lives alone, demonstrating the model's sustainability. The combination of statutory insurer coverage and streamlined approval creates an ideal market environment.

Pharma co-marketing arrangements deliver the highest margins (35-45%) by eliminating patient acquisition costs while providing 10%+ royalties on companion drug sales. CureApp's Shionogi partnership exemplifies this model's potential for Asian markets.

Mental health, diabetes, and musculoskeletal conditions drive the strongest growth due to high prevalence, clear clinical endpoints, and measurable cost savings. These areas combine large addressable markets with proven reimbursement precedent.

Looking for the latest market trends? We break them down in sharp, digestible presentations you can skim or share.

Which digital therapeutics companies or startups have scaled profitably, and what models did they use to achieve that?

Several DTx companies have achieved profitability or near-profitability using distinct reimbursement strategies tailored to their target markets.

Omada Health filed for IPO with 56% year-over-year revenue growth and near EBITDA break-even, scaling through employer contracts and commercial insurer coverage for diabetes and obesity management. Their subscription model with outcomes guarantees appeals to self-insured employers who benefit directly from reduced healthcare costs.

Kaia Health achieved profitability on German DiGA reimbursement alone, generating €21M ARR from statutory insurer coverage for musculoskeletal pain and COPD. The company leveraged Germany's fast-track pathway to build sustainable revenue before expanding to other European markets through France's PECAN pathway.

CureApp built a profitable business in Japan through national insurance coverage for smoking cessation and hypertension management, bundled with physician counseling codes. Their partnership with Shionogi provides additional royalty revenue, demonstrating how pharma collaborations enhance DTx economics.

Big Health scaled Sleepio through dual-channel reimbursement: NHS coverage in the UK plus employer contracts covering 800,000 lives through Evernorth's digital formulary. This multi-market approach reduces dependency on any single payer system.

DarioHealth's acquisition of Twill targets 80-85% gross margins by 2025 through integrated chronic disease management platform serving multiple payer channels simultaneously.

What kind of clinical evidence, certification, or regulatory approval is usually needed to secure reimbursement?

Payers require robust clinical evidence demonstrating both medical efficacy and economic value before approving DTx reimbursement.

Randomized controlled trials represent the gold standard for regulatory approval across all major markets. FDA requires Level I or II clinical studies for de novo or 510(k) clearance, while Germany's DiGA pathway accepts prospective RCTs or strong real-world evidence within 12 months of provisional listing. The evidence must demonstrate "positive care effect" through medical benefit or process improvement.

Health economic modeling has become equally critical as clinical data. Payers want to see cost-effectiveness analyses showing ROI within defined time horizons. NICE's approval of Sleepio relied heavily on demonstrated £15 per patient savings in primary care drug costs. German DiGA assessments require economic evaluation alongside clinical outcomes.

Data security and interoperability certifications are increasingly mandatory. ISO 27001, GDPR compliance, and HIPAA adherence now appear in most RFPs. EHR integration capabilities and post-market surveillance plans are standard requirements for sustained coverage.

Real-world evidence collection during commercial use supports ongoing reimbursement decisions. Many pathways provide provisional coverage while companies generate additional outcome data, making adaptive evidence strategies essential for long-term success.

If you need to-the-point data on this market, you can download our latest market pitch deck here

How are emerging reimbursement models for digital therapeutics likely to evolve in 2026 and beyond?

Reimbursement models are evolving toward value-based contracts tied directly to measurable clinical outcomes and cost savings.

CMS precedent will accelerate commercial payer adoption across the US. Once Medicare establishes payment rates through HCPCS supply codes, commercial insurers typically follow within 12-18 months, creating a cascade effect for FDA-cleared DTx. This pattern has already begun with mental health and chronic disease applications.

Pan-European alignment through the Health Data Space and HTA Regulation (effective January 2025) will streamline cross-border evidence submission. DTx approved through Germany's DiGA pathway will fast-track into France's PECAN system and vice versa, reducing regulatory burden and time-to-market.

Asia-Pacific markets are leapfrogging traditional approval processes. Japan's success with CureApp and Korea's draft economic evaluation guidelines are prompting Singapore and Australia to pilot bundled SaMD tariffs. This creates opportunities for companies to achieve multi-country coverage with unified evidence packages.

Integration with remote monitoring and AI-driven personalization will enhance value propositions and justify premium reimbursement rates. Payers increasingly want DTx that can predict and prevent costly interventions, not just treat existing conditions.

Planning your next move in this new space? Start with a clean visual breakdown of market size, models, and momentum.

What are the key barriers to reimbursement and how are companies overcoming them?

Clinical validation costs and regulatory complexity remain the primary barriers to DTx reimbursement, but companies are developing innovative solutions to overcome these challenges.

• Clinical Evidence Requirements: High-quality RCTs can cost $2-5M and take 18-24 months. Companies like Akili are using adaptive trial designs and leveraging real-world evidence from initial markets to satisfy requirements in subsequent jurisdictions.
• Fragmented Payer Landscapes: Different coverage criteria across payers create complexity. Companies are contracting through pharmacy benefit managers and digital formularies (Evernorth, CVS) to reach multiple plans simultaneously, reducing individual payer negotiation burden.
• Regulatory Complexity in Asia: Varying approval pathways slow market access. Industry groups in Korea are pushing for unified HIRA guidelines for economic evaluation, while companies are building region-specific evidence packages tailored to local requirements.
• Data Security Concerns: Privacy and cybersecurity requirements add compliance costs but raise barriers to entry. Leading companies are obtaining ISO 27001, GDPR, and HIPAA certifications proactively, turning compliance into competitive advantage.
• Provider Adoption Challenges: EHR integration and workflow compatibility issues slow uptake. Companies are investing in seamless integration tools and providing dedicated support for clinical implementation.

Which therapeutic areas show the strongest growth and reimbursement potential moving forward?

Mental health leads DTx reimbursement growth with new CMS digital mental health codes and strong employer demand driving expansion.

Depression, anxiety, insomnia, and ADHD applications benefit from first-line recommendations in NICE and USPSTF guidelines. Akili's EndeavorRx achieved both FDA clearance and commercial payer coverage for pediatric ADHD, while multiple anxiety and depression apps have gained DiGA listing in Germany. The high prevalence and measurable outcomes make mental health particularly attractive to payers.

Metabolic and obesity care represents enormous growth potential as employers seek alternatives to expensive GLP-1 medications. Companies like Hims & Hers are expanding into DTx-supported weight management, while Omada Health's diabetes prevention program demonstrates sustainable ROI for employers through reduced pharmaceutical costs.

Musculoskeletal and chronic pain management offers strong reimbursement potential due to opioid crisis concerns. Kaia Health's profitability on MSK applications and the emergence of RTM codes for sensor-guided exercise create favorable conditions for expansion. VR-based pain management through AppliedVR's RelieVRx achieved Medicare coverage under durable medical equipment benefits.

Cardiovascular health shows promise through proven real-world evidence. CureApp HT's demonstrated blood pressure reduction and reimbursement in Japan provides a template for hypertension management globally. The combination of high prevalence and clear clinical endpoints appeals to payers seeking measurable outcomes.

Conclusion

Sources

1. APA Services - Wellness or treatment in digital mental health
2. Aimed Alliance - Prescription Digital Therapies Report
3. Xealth - CMS Will Start Paying for DTx
4. Chronic Care Staffing - 2025 RPM CPT Codes Guide
5. BfArM - Digital Health Applications (DiGA)
6. AOK - Apps auf Rezept
7. HAS France - PECAN Guide
8. ICT Health - PECAN France Fast-Track
9. NHS England - MedTech Funding Mandate
10. NICE - Sleepio Guidance
11. MHLW Japan - Program Medical Device Evaluation
12. E-JYMS - Digital Therapeutics in Korea
13. DarioHealth - Twill Acquisition
14. Straits Research - Digital Therapeutics Market
15. Fierce Healthcare - DarioHealth Twill
16. Cigna - Prescription Digital Therapeutics Policy
17. CompWorth - Big Health Revenue Analysis
18. NICE - App-based Insomnia Treatment
19. MMIT Network - Highmark Coverage Decision
20. Stock Analysis - Omada Health Revenue
21. Reuters - Omada Health IPO Filing
22. PitchBook - Kaia Health Company Profile
23. Axios - Medicare Digital Mental Health Payment
24. EndeavorRx - Frequently Asked Questions
25. Investors.com - Hims & Hers Weight Loss Analysis
26. Accretive Edge - Digital Health Trends 2026